Aarti Drugs' Baddi facility in Himachal Pradesh gets 3 US FDA Form 483 observations

Aarti Drugs said its subsidiary Pinnacle Life Science received three Form 483 observations from the US FDA after an inspection of its Baddi formulations facility between November 2 and 6. None of the observations was related to data integrity, and the company said there was no financial or operational impact.